To meet the beam power requirements of 400 kW at the fragmentation target for facility for Rare Isotope Beams (FRIB), simultaneous acceleration of two-charge states should be used for heavier ions. These intense multi-charged ion beams will be produced by a 28 GHz electron cyclotron resonance (ECR) ion source at a high voltage of 35 kV. After extraction, the ion beam will be pre-accelerated to 12 keV/u with a 50 kV platform, transported down to an achromatic charge state selection (CSS) system followed by a vertical transport line, and then injected into a radio frequency quadrupole accelerator. The TRACK code developed at ANL is used to perform the simulations of the ECR beam extraction and low energy beam transport for FRIB. In this study, we include the magnetic field of ECR ion source into simulations. Different initial beam conditions as well as different space charge neutralization levels are tested for the ECR beamline. The beam loss in CSS system and the corresponding protective measures are discussed. The detailed results about the beam dynamic simulation and beam loss in CSS system will be presented in this paper.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1063/1.4934621 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Infrared and Visible Image Alignment Method Based on Gradient Distribution Properties and Scale-Invariant Features in Electric Power Scenes.
J Imaging
January 2025
State Key Laboratory of Power Transmission Equipment Technology, School of Electrical Engineering, Chongqing University, Chongqing 400044, China.
In grid intelligent inspection systems, automatic registration of infrared and visible light images in power scenes is a crucial research technology. Since there are obvious differences in key attributes between visible and infrared images, direct alignment is often difficult to achieve the expected results. To overcome the high difficulty of aligning infrared and visible light images, an image alignment method is proposed in this paper.
View Article and Find Full Text PDFSemaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.
Lancet Diabetes Endocrinol
January 2025
Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. Electronic address:
Background: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF and type 2 diabetes, subcutaneous once weekly semaglutide 2·4 mg conferred improvements in heart failure-related symptoms and physical limitations, bodyweight, and other heart failure outcomes. We aimed to determine whether these effects of semaglutide differ according to baseline HbA.
View Article and Find Full Text PDFDevelopment and application of 3D cardiac tissues derived from human pluripotent stem cells.
Drug Metab Pharmacokinet
January 2025
Department of Clinical Regenerative Medicine, Fujita Medical Innovation Center Tokyo, Fujita Health University, Tokyo, Japan; Department of Cardiology, Keio University School of Medicine, Tokyo, Japan. Electronic address:
Recently human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have become an attractive platform to evaluate drug responses for cardiotoxicity testing and disease modeling. Moreover, three-dimensional (3D) cardiac models, such as engineered heart tissues (EHTs) developed by bioengineering approaches, and cardiac spheroids (CSs) formed by spherical aggregation of hPSC-CMs, have been established as useful tools for drug discovery and transplantation. These 3D models overcome many of the shortcomings of conventional 2D hPSC-CMs, such as immaturity of the cells.
View Article and Find Full Text PDFInnovating chitosan-based bioinks for dermal wound healing: Current progress and future prospects.
Int J Biol Macromol
January 2025
Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Tissue Engineering and Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran; Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran; NanoBiotechnology & Regenerative Medicine Innovation Group, Noavarn Salamat ZHINO (PHC), Tehran, Iran. Electronic address:
The field of three-dimensional (3D) bio/printing, known as additive manufacturing (AM), heavily relies on bioinks possessing suitable mechanical properties and compatibility with living cells. Among the array of potential hydrogel precursor materials, chitosan (CS) has garnered significant attention due to its remarkable physicochemical and biological attributes. These attributes include biodegradability, nontoxicity, antimicrobial properties, wound healing promotion, and immune system activation, making CS a highly appealing hydrogel-based bioink candidate.
View Article and Find Full Text PDFDescriptive epidemiology and prognostic factors of atypical teratoid/rhabdoid tumors in the United States, 2001-2021.
Neurosurg Rev
January 2025
Department of Neurosurgery, The First Hospital of Jilin University, Changchun, China.
Atypical teratoid rhabdoid tumor (AT/RT) is a rare embryonal central nervous system tumor with a dismal prognosis that occurs mostly in early childhood. Since recent epidemiological and prognostic information is limited, we aimed to describe and analyze AT/RT-related incidences, temporal trends and prognostic factors. Incidence and survival data between 2001 and 2021 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!